Novavax Inc

As the Novavax COVID-19 vaccine enters the U.S. market, the people behind the company are coming into question. Who owns Novavax?

Novavax has a combined influenza and COVID-19 vaccine awaiting clinical trials right now. Is NVAX stock a buy or sell?

Novavax is a key player in the COVID-19 vaccine race. NVAX stock has reacted to vaccine updates. Will Novavax be able to compete with Pfizer and Moderna?

This year, Novavax stock has risen over 3,400 percent. Is NVAX stock a buy or sell at this price?

According to Novavax, ~64.0 million RSV infections occur every year on a global basis. The global cost of RSV exceeds $88.0 billion.

The cannabis industry is doing its own research amid COVID-19. Researchers discovered that marijuana might have properties to fight the coronavirus.

Investors have poured on Novavax stock as the company races to bring a COVID-19 vaccine to the market.

Pfizer (NYSE:PFE) stock rose 2.4% in pre-market trading at 7:51 AM ET today. The company’s experimental COVID-19 vaccine showed positive results.

Today at 6:22 AM ET, Norwegian Cruise Line Holdings (NASDAQ:NCLH) stock rose 12% to $17.90 in the pre-market session. What can investors expect?

Today at 6:32 AM ET, Carnival (NYSE:CCL) stock rose 11% to $16.00 in the pre-market session. The company has been benefiting from positive developments.

Today at 4:37 AM ET, Novavax stock rose 20% to $55.40 in the pre-market session. The company started the Phase I study of NVX-CoV2373.

Carnival stock rose 15.2% on Monday and closed at $14.72 with a market cap of $10.7 billion. The stock price rose due to hope about a COVID-19 vaccine.

Novavax stock rose almost 133% in the week ended May 15 and closed at $43.63. The stock has generated returns of 552% in the last 12 months.

Today at 4:30 AM ET, Novavax stock rose 38% to $33.74 in the pre-market session. The company received funding for its COVID-19 vaccine candidate.

On February 28, Novavax (NVAX) issued a press release announcing results from the first-ever Phase 3 trial for PrepareTM.

Novavax (NVAX) reported first-quarter results on May 2.

Today, Novavax (NVAX) is trading close to $0.70, which is about 67.13% lower than its previous closing price.

On February 22, Amarin (AMRN) closed at $19.87, 14% higher than its previous closing price and 746% higher than its 52-week low of $2.35.

Novavax has entered into a key grant agreement with the Bill and Melinda Gates Foundation, which is the current source of its revenue.

Of the nine analysts covering Agios Pharmaceuticals (AGIO) in March 2018, one gave it a “strong buy” rating, and six gave it a “buy” rating.

A clinical-stage biotech company, Novavax’s (NVAX) pipeline includes products for influenza, Ebola virus, and Zika virus. In November, two of seven analysts gave NVAX stock a “strong buy” rating.

Eli Lilly and Co.’s (LLY) overall business is classified into two business segments—Human Pharmaceuticals and Animal Health.

Bristol-Myers Squibb (BMY) is expected to report revenue growth of over 11% to $4.7 billion in its 2Q16 results on July 28, 2016.

Incyte is a biopharmaceutical company that’s focused on the discovery, development, and commercialization of oncology drugs.